Gujarat Themis Biosyn Limited (NSE:GUJTHEM)

Market Cap	32.29B
Revenue (ttm)	1.55B
Net Income (ttm)	526.59M
Shares Out	n/a
EPS (ttm)	4.83
PE Ratio	61.31
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,663
Average Volume	55,748
Open	308.45
Previous Close	316.15
Day's Range	303.90 - 322.00
52-Week Range	192.35 - 530.00
Beta	n/a
RSI	56.32
Earnings Date	May 13, 2025

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1981
• Employees: 159
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUJTHEM

Financial Performance

In 2023, Gujarat Themis Biosyn's revenue was 1.70 billion, an increase of 14.45% compared to the previous year's 1.48 billion. Earnings were 591.63 million, an increase of 2.06%.